Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jun 6;24(1):565.
doi: 10.1186/s12879-024-09407-9.

Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study

Lin Gan  1 , Xiaoxin Xie  1 , Yanhua Fu  1 , Xiaoyan Yang  1 , Shujing Ma  2 , Linghong Kong  2 , Chunli Song  1 , Yebing Song  1 , Tingting Ren  1 , Hai Long  3
Affiliations

Safety and adherence of bictegravir/emtricitabine/tenofovir alafenamide for HIV post-exposure prophylaxis among adults in Guiyang China: a prospective cohort study

Lin Gan et al. BMC Infect Dis. .

Abstract

Background: The effectiveness of post-exposure prophylaxis (PEP) depends on participants adherence, making it crucial to assess and compare regimen options to enhance human immunodeficiency virus (HIV) prophylaxis strategies. However, no prospective study in China has shown that the completion rate and adherence of single-tablet regimens in HIV PEP are higher than those of multi-tablet preparations. Therefore, this study aimed to assess the completion rate and adherence of two HIV PEP regimens.

Methods: In this single-center, prospective, open-label cohort study, we included 179 participants from May 2022 to March 2023 and analyzed the differences in the 28-day medication completion rate, adherence, safety, tolerance, and effectiveness of bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) and tenofovir disoproxil fumarate, emtricitabine, and dolutegravir (TDF/FTC + DTG).

Results: The PEP completion rate and adherence were higher in the BIC/FTC/TAF group than in the TDF/FTC + DTG group (completion rate: 97.8% vs. 82.6%, P = 0.009; adherence: 99.6 ± 2.82% vs. 90.2 ± 25.29%, P = 0.003). The incidence of adverse reactions in the BIC/FTC/TAF and TDF/FTC + DTG groups was 15.2% and 10.3% (P = 0.33), respectively. In the TDF/FTC + DTG group, one participant stopped PEP owing to adverse reactions (1.1%). No other participants stopped PEP due to adverse events.

Conclusions: BIC/FTC/TAF and TDF/FTC + DTG have good safety and tolerance as PEP regimens. BIC/FTC/TAF has a higher completion rate and increased adherence, thus, is recommended as a PEP regimen. These findings emphasize the importance of regimen choice in optimizing PEP outcomes.

Trial registration: The study was registered in the Chinese Clinical Trial Registry (registration number: ChiCTR2200059994(2022-05-14), https://www.chictr.org.cn/bin/project/edit?pid=167391 ).

Keywords: Bictegravir/emtricitabine/tenofovir alafenamide; HIV post-exposure prophylaxis; Integrase strand transfer inhibitors; Safety; Single-tablet regimen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart showing participant inclusion and attendance to follow-up in the study
Fig. 2
Fig. 2
HIV post-exposure prophylaxis (PEP) completion rate and adherence. a PEP completion rates in the BIC/FTC/TAF and TDF/FTC + DTG groups. b Adherence of the BIC/FTC/TAF and TDF/FTC + DTG groups. Abbreviations: BIC/FTC/TAF: bictegravir, emtricitabine, and tenofovir alafenamide; TDF/FTC + DTG: tenofovir disoproxil fumarate, emtricitabine, and dolutegravir
Fig. 3
Fig. 3
Changes in biomarkers of different PEP regimens from baseline to 28 days
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. UNAIDS. The path that ends AIDS [EB/OL]. 2023. https://ncaids.chinacdc.cn/xxgx/yqbh/202307/W020230714332118740538.pdf. Accessed 30 Jan 2024.
    1. National Bureau of Disease Control and Prevention. [EB/OL]. 2019. https://www.gov.cn/xinwen/2019-10/13/content_5439036.htm. Accessed 27 May 2023.
    1. Cresswell F, Asanati K, Bhagani S, Boffito M, Delpech V, Ellis J, et al. UK guideline for the use of HIV post-exposure prophylaxis 021. HIV Med. 2022;23:494–545. doi: 10.1111/hiv.13208. - DOI - PubMed
    1. Siedner MJ, Tumarkin E, Bogoch II. HIV post-exposure prophylaxis (PEP) BMJ. 2018;363:k4928. doi: 10.1136/bmj.k4928. - DOI - PubMed
    1. Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270:1197–1199. doi: 10.1126/science.270.5239.1197. - DOI - PubMed

MeSH terms